XBiotech Inc. Daily Stock Analysis

Daily Stock Analysis, XBIT, XBiotech Inc, priceseries

XBiotech Inc. Daily Stock Analysis
Stock Information
Open
9.50
Close
9.24
High
9.50
Low
9.19
Previous Close
9.41
Daily Price Gain
-0.17
YTD High
11.90
YTD High Date
Jan 11, 2022
YTD Low
9.10
YTD Low Date
Feb 24, 2022
YTD Price Change
-2.28
YTD Gain
-19.79%
52 Week High
20.25
52 Week High Date
Mar 15, 2021
52 Week Low
9.10
52 Week Low Date
Feb 24, 2022
52 Week Price Change
-9.50
52 Week Gain
-50.69%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 17. 2017
12.27
Mar 28. 2017
16.94
26 Trading Days
38.03%
Link
LONG
Jun 1. 2017
9.33
Jun 5. 2017
9.82
2 Trading Days
5.20%
Link
LONG
Sep 25. 2018
2.93
Oct 8. 2018
3.22
9 Trading Days
10.06%
Link
LONG
Dec 11. 2018
4.32
Dec 26. 2018
5.17
10 Trading Days
19.64%
Link
LONG
Feb 4. 2019
7.24
Feb 8. 2019
7.89
4 Trading Days
9.01%
Link
LONG
Aug 13. 2019
7.40
Aug 26. 2019
8.07
9 Trading Days
9.07%
Link
LONG
Aug 30. 2019
8.35
Oct 2. 2019
9.80
22 Trading Days
17.32%
Link
LONG
Nov 8. 2019
11.09
Nov 22. 2019
12.95
10 Trading Days
16.73%
Link
LONG
Apr 3. 2020
11.49
Apr 20. 2020
13.06
10 Trading Days
13.67%
Link
LONG
Aug 10. 2020
15.63
Aug 27. 2020
18.31
13 Trading Days
17.13%
Link
LONG
Oct 19. 2021
13.40
Nov 10. 2021
15.11
16 Trading Days
12.79%
Link
Company Information
Stock Symbol
XBIT
Exchange
NasdaqGS
Company URL
http://www.xbiotech.com
Company Phone
512-386-2930
CEO
John Simard
Headquarters
Texas
Business Address
8201 E. RIVERSIDE DRIVE, BUILDING 4, SUITE 100, AUSTIN, TX 78744
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001626878
About

XBiotech, Inc. operates as a clinical-stage biopharmaceutical company, which engages in discovering and developing True Human monoclonal antibodies for treating a variety of diseases. It develops Xilonix™ for the treatment of colorectal cancer. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Description

XBiotech Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer. It has also investigating its lead product candidate in various clinical trials for other inflammatory conditions, including vascular disease, type II diabetes, acne, psoriasis, pyoderma gangrenosum, and hidradenitis suppurativa, as well as staphylococcus aureus infection, influenza, and clostridium difficile infection diseases. XBiotech, Inc. was founded in 2005 and is headquartered in Austin, Texas.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading